Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Driven by a cyclical rebound across overweight life sciences tools holdings, while initiating turnaround stakes in Biogen and Humana and exiting 14 positions.
Full Quick Take
Driven by a cyclical rebound across overweight life sciences tools holdings, while initiating turnaround stakes in Biogen and Humana and exiting 14 positions.
Eagle Capital has recycled capital away from the AI capex boom, which now represents over 30% of the S&P 500 and is pricing optimistic cases without sufficient downside consideration.
Full Quick Take
Eagle Capital has recycled capital away from the AI capex boom, which now represents over 30% of the S&P 500 and is pricing optimistic cases without sufficient downside consideration.
Bretton Fund lagged the market in Q2 2026 by avoiding the unsustainable AI semiconductor boom, refusing to chase Micron up 600% and memory stocks at absurd valuations. UnitedHealth's turnaround added 2.5% after rebounding 80% from crisis lows.
Full Quick Take
Bretton Fund lagged the market in Q2 2026 by avoiding the unsustainable AI semiconductor boom, refusing to chase Micron up 600% and memory stocks at absurd valuations. UnitedHealth's turnaround added 2.5% after rebounding 80% from crisis lows.
Sycamore Mid Cap Value underperformed in Q2 2026 as extreme AI-driven concentration penalized diversified value managers. The strategy avoided parabolic semiconductor and tech hardware stocks on valuation discipline, costing 323 basis points.
Full Quick Take
Sycamore Mid Cap Value underperformed in Q2 2026 as extreme AI-driven concentration penalized diversified value managers. The strategy avoided parabolic semiconductor and tech hardware stocks on valuation discipline, costing 323 basis points.
Diamond Hill's Small-Mid Cap Strategy underperformed in Q2 2026 as AI momentum dominated, but the manager used volatility to upgrade portfolio quality. Health care, particularly managed care, was the standout performer with strong positioning in Humana and new addition Centene.
Full Quick Take
Diamond Hill's Small-Mid Cap Strategy underperformed in Q2 2026 as AI momentum dominated, but the manager used volatility to upgrade portfolio quality. Health care, particularly managed care, was the standout performer with strong positioning in Humana and new addition Centene.
ICON exemplified the strategy: aggressively buying a quality business at a 15% free cash flow yield during peak pessimism, then capturing a 90% gain as uncertainty receded.
Full Quick Take
ICON exemplified the strategy: aggressively buying a quality business at a 15% free cash flow yield during peak pessimism, then capturing a 90% gain as uncertainty receded.
Harris Associates' concentrated value strategy underperformed in Q2 2026 as markets favored AI beneficiaries. The manager added Marsh & McLennan on insurance rate weakness and maintained conviction in Salesforce and Intercontinental Exchange despite AI disruption concerns.
Full Quick Take
Harris Associates' concentrated value strategy underperformed in Q2 2026 as markets favored AI beneficiaries. The manager added Marsh & McLennan on insurance rate weakness and maintained conviction in Salesforce and Intercontinental Exchange despite AI disruption concerns.
The Davenport Value & Income Fund underperformed in Q2 2026 as AI and semiconductor momentum dominated markets, but management maintains disciplined value orientation. Top performers included Texas Instruments, Cisco, and health insurers as underwriting cycles improved.
Full Quick Take
The Davenport Value & Income Fund underperformed in Q2 2026 as AI and semiconductor momentum dominated markets, but management maintains disciplined value orientation. Top performers included Texas Instruments, Cisco, and health insurers as underwriting cycles improved.
Smead Value Fund runs a concentrated 25-30 stock portfolio with 96% active share, deliberately avoiding expensive technology stocks. Q2 winners were mall REITs benefiting from record occupancy and pricing power.
Full Quick Take
Smead Value Fund runs a concentrated 25-30 stock portfolio with 96% active share, deliberately avoiding expensive technology stocks. Q2 winners were mall REITs benefiting from record occupancy and pricing power.
Diamond Hill's Large Cap Fund underperformed by 1,052 basis points in Q2 2026, driven almost entirely by avoiding AI beneficiaries like Micron while the technology sector surged 81%.
Full Quick Take
Diamond Hill's Large Cap Fund underperformed by 1,052 basis points in Q2 2026, driven almost entirely by avoiding AI beneficiaries like Micron while the technology sector surged 81%.
Dodge & Cox Stock Fund underperformed in Q2 2026 as narrow market leadership favored growth over value. The Fund used AI disruption fears to initiate positions in Visa, Thermo Fisher, and KKR at attractive valuations.
Full Quick Take
Dodge & Cox Stock Fund underperformed in Q2 2026 as narrow market leadership favored growth over value. The Fund used AI disruption fears to initiate positions in Visa, Thermo Fisher, and KKR at attractive valuations.
The fund underperformed in Q2 2026 as AI enthusiasm drove market returns. BNP Paribas led contributions with strong capital build and attractive valuation despite French economic concerns.
Full Quick Take
The fund underperformed in Q2 2026 as AI enthusiasm drove market returns. BNP Paribas led contributions with strong capital build and attractive valuation despite French economic concerns.
Oakmark Select underperformed in Q2 2026 as narrow AI-driven market leadership persisted, but the fund maintained its value discipline. Managed care holdings like Centene drove outperformance on stabilizing medical costs and improving reimbursement trends.
Full Quick Take
Oakmark Select underperformed in Q2 2026 as narrow AI-driven market leadership persisted, but the fund maintained its value discipline. Managed care holdings like Centene drove outperformance on stabilizing medical costs and improving reimbursement trends.
Magellan underperformed in Q2 2026 as semiconductor stocks surged 88% in bubble-like conditions the manager deliberately avoided to protect capital. The fund added to quality franchises outside AI themes now trading at post-Covid attractive valuations.
Full Quick Take
Magellan underperformed in Q2 2026 as semiconductor stocks surged 88% in bubble-like conditions the manager deliberately avoided to protect capital. The fund added to quality franchises outside AI themes now trading at post-Covid attractive valuations.
ClearBridge Value Strategy underperformed in Q2 despite solid absolute returns as AI-led growth rebounded, but value retained a substantial YTD lead. Strong selection in Alphabet, CVS, Micron and Taiwan Semi was offset by energy weakness.
Full Quick Take
ClearBridge Value Strategy underperformed in Q2 despite solid absolute returns as AI-led growth rebounded, but value retained a substantial YTD lead. Strong selection in Alphabet, CVS, Micron and Taiwan Semi was offset by energy weakness.
Orbis outperformed in volatile Q1 2026 through disciplined contrarian positioning. Semiconductor winners from AI boom offset healthcare losers from regulatory pressures and financial irregularities.
Full Quick Take
Orbis outperformed in volatile Q1 2026 through disciplined contrarian positioning. Semiconductor winners from AI boom offset healthcare losers from regulatory pressures and financial irregularities.
Sequoia Fund outperformed the market in 2025 with a 22.13% return. The letter details how the managers balanced valuation discipline and conviction across core positions, and lists key new purchases in MSA Safety, Accenture, and Align Technology.
Full Quick Take
Sequoia Fund outperformed the market in 2025 with a 22.13% return. The letter details how the managers balanced valuation discipline and conviction across core positions, and lists key new purchases in MSA Safety, Accenture, and Align Technology.
Meditation Capital is avoiding structural AI risk by selling GitLab and raising alarm over an AI capex bubble, while aggressively buying beaten-down health insurers Elevance and Molina for projected 25%+ IRRs as margins recover.
Full Quick Take
Meditation Capital is avoiding structural AI risk by selling GitLab and raising alarm over an AI capex bubble, while aggressively buying beaten-down health insurers Elevance and Molina for projected 25%+ IRRs as margins recover.
Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as a highly mispriced compounder.
Full Quick Take
Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as a highly mispriced compounder.
Driven by strong biotechnology stock selection, particularly argenx and Insmed benefiting from drug approvals. AI-enabled healthcare solutions like RadNet and Heartflow also contributed.
Full Quick Take
Driven by strong biotechnology stock selection, particularly argenx and Insmed benefiting from drug approvals. AI-enabled healthcare solutions like RadNet and Heartflow also contributed.
Bristlemoon underperformed due to defensive tariff positioning and concentrated portfolio volatility, but management expresses highest conviction ever in current holdings. New positions in APi Group, Salesforce, and UnitedHealth offer compelling risk-adjusted returns.
Full Quick Take
Bristlemoon underperformed due to defensive tariff positioning and concentrated portfolio volatility, but management expresses highest conviction ever in current holdings. New positions in APi Group, Salesforce, and UnitedHealth offer compelling risk-adjusted returns.
Strong contributions from Lloyds Banking and new positions in undervalued Molina Healthcare and Sysco Corporation demonstrate the fund's ability to capitalize on market inefficiencies.
Full Quick Take
Strong contributions from Lloyds Banking and new positions in undervalued Molina Healthcare and Sysco Corporation demonstrate the fund's ability to capitalize on market inefficiencies.
Oakmark Select outperformed in Q1 2025 despite negative returns, driven by financials and industrials strength. The fund is opportunistically repositioning during market weakness, adding Molina Healthcare at attractive valuations amid temporary Medicaid policy headwinds.
Full Quick Take
Oakmark Select outperformed in Q1 2025 despite negative returns, driven by financials and industrials strength. The fund is opportunistically repositioning during market weakness, adding Molina Healthcare at attractive valuations amid temporary Medicaid policy headwinds.
Harris Associates' concentrated value strategy underperformed in Q1 2025 despite contributions from ICE, Deere, and ConocoPhillips. Alphabet and IQVIA detracted on temporary headwinds.
Full Quick Take
Harris Associates' concentrated value strategy underperformed in Q1 2025 despite contributions from ICE, Deere, and ConocoPhillips. Alphabet and IQVIA detracted on temporary headwinds.
Parnassus Value underperformed in Q1 as tech holdings declined amid AI spending concerns and tariff uncertainty. The fund is rotating from defensive outperformers into quality franchises like JP Morgan and AMD at attractive valuations.
Full Quick Take
Parnassus Value underperformed in Q1 as tech holdings declined amid AI spending concerns and tariff uncertainty. The fund is rotating from defensive outperformers into quality franchises like JP Morgan and AMD at attractive valuations.
Heartland's disciplined value approach underperformed in Q4 as post-election speculation favored growth over value. The fund refuses to chase elevated valuations, maintaining focus on attractively priced businesses like Sysco, Willis Tower Watson, and Centene.
Full Quick Take
Heartland's disciplined value approach underperformed in Q4 as post-election speculation favored growth over value. The fund refuses to chase elevated valuations, maintaining focus on attractively priced businesses like Sysco, Willis Tower Watson, and Centene.
Oakmark Fund delivered solid Q4 performance while maintaining its value-focused approach of buying quality businesses at attractive prices. Wells Fargo led contributions on strong fundamentals and massive buybacks, while Centene detracted on overblown political concerns.
Full Quick Take
Oakmark Fund delivered solid Q4 performance while maintaining its value-focused approach of buying quality businesses at attractive prices. Wells Fargo led contributions on strong fundamentals and massive buybacks, while Centene detracted on overblown political concerns.
Oakmark Global Select underperformed in Q4 but used volatility to add quality names at discounts. Capital One led gains on deregulation hopes while Bayer dragged on litigation and guidance concerns.
Full Quick Take
Oakmark Global Select underperformed in Q4 but used volatility to add quality names at discounts. Capital One led gains on deregulation hopes while Bayer dragged on litigation and guidance concerns.
Oakmark Global underperformed in Q4 but maintains long-term outperformance through disciplined value investing. Capital One drove gains on deregulation hopes while Bayer weighed on performance amid litigation and guidance concerns.
Full Quick Take
Oakmark Global underperformed in Q4 but maintains long-term outperformance through disciplined value investing. Capital One drove gains on deregulation hopes while Bayer weighed on performance amid litigation and guidance concerns.
Vulcan Value Partners added four high-quality large-cap positions in Q3 2023 including Diageo, Marriott, Texas Instruments, and UnitedHealth Group, all previously owned companies with sustainable competitive advantages.
Full Quick Take
Vulcan Value Partners added four high-quality large-cap positions in Q3 2023 including Diageo, Marriott, Texas Instruments, and UnitedHealth Group, all previously owned companies with sustainable competitive advantages.